Why Abzena?
Our focused approach.
Craig Magee, Vice President, Business Development, Parviz Ayazi Shamlou, Senior Vice President, Science & Technology, and Eric Miller, Senior Director Scientific Projects will be available to provide you with an update on our expanded global capabilities from antibodies (mAbs) to recombinant vaccines and bioconjugates- including ADCs, radioconjugates, to oligonucleotides.
Event Details: